Update on current business operations of the Company
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ishita Drugs & Industries held a Board meeting on June 13, 2025 where the Managing Director briefed the Board on a planned upgradation of its manufacturing facility at Sanand, Ahmedabad to comply with the Revised Schedule M notification under the Drug Rules, 1945. The Company has appointed consultants for technical planning, finalized the design and layout which has been approved by the concerned regulatory authority, and has already begun implementation work. Additionally, the Company has submitted an application seeking an extension in the timeline for implementing the Revised Schedule M requirements.
The facility upgrade involves capital expenditure and operational adjustments to meet updated pharmaceutical manufacturing norms, which is necessary for the Company to continue compliant operations. The request for a timeline extension suggests the Company may need more time to complete the upgrade within the originally prescribed deadlines.